HSPA9 and cancer: Complementation of SHetA2 with paclitaxel anti-cancer activity was predicted based on SHetA2 disruption of mortalin function at the centrosome and the ability of cancer cells to bypass taxane-induced cell death by re-duplicating centrosomes outside of the normal cell cycle process.